New NP-C Drug Trial A clinical trial is expected to begin in the summer of 2014 using a Histone Deacetylase Inhibitors (HDACi). The goal of the Phase 1 clinical trial will be to establish the safety and tolerability of a - Niemann-Pick disease, type C - Document - PDFSEARCH.IO

First Page	Meta Content
	New NP-C Drug Trial A clinical trial is expected to begin in the summer of 2014 using a Histone Deacetylase Inhibitors (HDACi). The goal of the Phase 1 clinical trial will be to establish the safety and tolerability of a Add to Reading List Document Date: 2013-12-11 15:45:47 Open Document File Size: 55,05 KB Share Result on Facebook City Rochester / / Facility University of Notre Dame / Mayo Clinic / Washington University / College of Science / National Institutes of Health Clinical Center / Maxfield laboratory / Columbia University / / IndustryTerm treatment for NPC1 disease / treatment of this devastating disorder / / MedicalCondition ataxia / dysarthria / dementia / disease / seizures / dysphagia / neurological manifestation / disorder / NPC1 disease / dystonia / vertical supranuclear gaze palsy / / Organization Columbia University / National Institute of Health / Food and Drug Administration / National Institutes of Health Clinical Center / College of Science / Cornell / NIH Clinical Center / FDA / Washington University / University of Notre Dame / / Person Olaf Wiest / Paul Helquist / Fred Maxfield / Porter / Steven Sturley / Marc Patterson / Ory / Greg Crawford / / Position Porter / Dean / / ProvinceOrState Minnesota / / SocialTag Medical statistics NPC1 Clinical research Design of experiments Clinical trial Biomarker Surrogate endpoint Histone deacetylase inhibitor Niemann-Pick disease, type C Medicine

New NP-C Drug Trial A clinical trial is expected to begin in the summer of 2014 using a Histone Deacetylase Inhibitors (HDACi). The goal of the Phase 1 clinical trial will be to establish the safety and tolerability of aAdd to Reading List